News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Treatment-experienced people news

Show

From To
New and experimental HIV treatments
Can people with resistant HIV omit NRTIs when switching from a failing regimen?

Omitting nucleoside reverse transcriptase inhibitors (NRTIs) when switching from a non-suppressive regimen to a new combination with at least two active agents can reduce pill burden and

Published
07 March 2013
By
Liz Highleyman
Treatment outcomes and life expectancy
Australian researchers project that many HIV-positive people will run out of treatment options

Running out of antiretroviral treatment options may severely curtail the life expectancy of people with HIV in resource-rich countries, according to Australian research published in

Published
22 January 2013
By
Michael Carter
Resistance
Prevalence of drug-resistant HIV has fallen dramatically among antiretroviral-experienced patients in Western Europe

There has been a significant fall in the proportion of HIV-positive people in Western Europe with experience of HIV treatment who have resistance to antiretroviral

Published
22 January 2013
By
Michael Carter
Treatment-experienced people
Any reduction in viral load has immunologic benefits for people with HIV who have triple-class treatment failure

HIV therapy that achieves even modest reductions in viral load can have profound immunological benefits for people with triple-class treatment failure, European investigators report in the online edition

Published
08 January 2013
By
Michael Carter
Treatment-experienced people
Redefining Expanded Access Programs for patients with MDR-HIV

It is time to create a new paradigm to break the vicious cycle of single drug access that has failed these patients.

Published
04 December 2012
From
GMHC Treatment Issues
Changing treatment
Raltegravir-resistant HIV stays susceptible to dolutegravir in lab

HIV resistant to the integrase inhibitor raltegravir and isolated from patients taking a failing raltegravir regimen remained largely susceptible to the integrase inhibitor dolutegravir in phenotypic susceptibility testing. Raltegravir-resistant virus carrying a mutation at position Q148 had more reduced susceptibility to dolutegravir than isolates with other raltegravir mutations.

Published
13 November 2012
From
International AIDS Society
HIV treatment
The generic generation

In the next few years, some of the most widely used HIV drugs will come off patent in the UK. Gus Cairns asks: what are the

Published
22 October 2012
From
HIV treatment update
Resistance
Mutation breaks HIV's resistance to drugs

The human immunodeficiency virus (HIV) can contain dozens of different mutations, called polymorphisms. In a recent study an international team of researchers found that one of those mutations, called 172K, made certain forms of the virus more susceptible to treatment. Soon, doctors will be able to use this knowledge to improve the drug regimen they prescribe to HIV-infected individuals.

Published
14 September 2012
From
Science Daily
Treatment-experienced people
Booster HIV Drug Can Be Dropped

In a randomized trial, switching away from the booster drug allowed treatment-experienced patients to keep HIV under control and reduced toxicity, according to David Wohl, MD, of the University of North Carolina in Chapel Hill.

Published
13 September 2012
From
MedPage Today
Diabetes
Glucose metabolism worsens in HIV treatment-experienced taking NRTI-sparing regimens

Italian investigators have found evidence of worsening glucose tolerance in highly treatment-experienced HIV-positive patients treated with nucleoside-sparing regimens. The small study, which is published in the online edition

Published
24 August 2012
By
Michael Carter
← Prev1...23456...16Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.